Condition (MeSH)
Dengue
ClinicalTrials.gov lists 282 trials for Dengue or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 37.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
275 of the 282 trials are tagged with Dengue itself; the rest are tagged with a narrower condition beneath it.
When did Dengue trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 25
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 16 |
| 2025 | 22 |
| 2024 | 21 |
| 2023 | 17 |
| 2022 | 15 |
| 2021 | 17 |
| 2020 | 11 |
| 2019 | 8 |
| 2018 | 12 |
| 2017 | 9 |
Showing 10 of 25 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 19 trials starting in 2026 and about 20 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 13 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 194 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Dengue trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 59 |
| Phase 1/2 | 9 |
| Phase 2 | 49 |
| Phase 2/3 | 6 |
| Phase 3 | 27 |
| Phase 4 | 1 |
| Not applicable | 47 |
| Observational | 84 |
How many Dengue trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 10 |
| Recruiting | 25 |
| Enrolling by invitation | 3 |
| Active, not recruiting | 13 |
| Completed | 176 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Dengue trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 37 |
| Sanofi Pasteur, a Sanofi Company | 30 |
| Takeda | 17 |
| U.S. Army Medical Research and Development Command | 15 |
| Sanofi | 6 |
Showing 5 of 9 sponsors.
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| CYD Dengue Vaccine | 11 |
| TDV | 6 |
| rDEN2Δ30-7169 | 6 |
| data collection | 5 |
| Tetravalent Dengue Vaccine (TDV) | 4 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Dengue trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Dengue Fever | 600 | 5 |
| Appendicitis | 511 | 18 |
| Road Traffic Accident | 262 | 5 |
| Gastroenteritis | 237 | 16 |
| Urinary Tract Infection | 220 | 4 |
Showing 5 of 10 adverse events.
Which publications cover Dengue? (393)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine. | Expert review of vaccines | 2025 | Yes |
| Randomized, double-blind, placebo-controlled, phase 3 trial to demonstrate lot-to-lot consistency of 3 lots of the simplified formulation of Butantan-dengue vaccine. | Vaccine | 2025 | Yes |
| Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2025 | Yes |
| Dengue virus and lipid metabolism: unravelling the interplay for future therapeutic approaches. | Emerging microbes & infections | 2025 | Yes |
| Operational challenges and lessons learned from conducting febrile surveillance in a long-term randomized dengue vaccine trial in Latin America and Asia-Pacific. | Travel medicine and infectious disease | 2025 | Yes |
Showing 5 of 393 publications.
Prevalence (78)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Dengue fever | Annual incidence | 1-9 / 1 000 000 | United Kingdom | GB | Exact |
| Dengue fever | Annual incidence | 1-9 / 1 000 000 | United Kingdom | GB | Unspecified |
| Dengue fever | Annual incidence | 1-9 / 1 000 000 | United Kingdom | GB | Exact |
| Dengue fever | Annual incidence | <1 / 1 000 000 | Slovakia | Not stated | Unspecified |
| Dengue fever | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
Showing 5 of 78 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Dengue fever | 99828 | Exact | Orphadata Science knowledge files, Product 1 |
| Dengue fever | 99828 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.